Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Ivim Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxIvim Health
Cost-first shoppers who want a compounded GLP-1 quoted with the program charge folded in rather than added at checkout.
Visit Ivim HealthThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 57. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Ivim Health still earns a C — Cost-first shoppers who want a compounded GLP-1 quoted with the program charge folded in rather than added at checkout.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Ivim Health |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 57/100 |
| Semaglutide / mo | $99/mo | $149/mo (starting dose, medication and program fee, compounded) |
| Tirzepatide / mo | $149/mo | $224/mo (starting dose, medication and program fee, compounded) |
| Semaglutide / yr (modeled) | $1,188 | $1,788 |
| Tirzepatide / yr (modeled) | $1,788 | $2,688 |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #305 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Ivim Health
57/100Where the value is
- Both molecules are priced on one page, each quoted as medication and program charge included rather than as a bare drug price
- A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
- The first month of the membership is free
The tradeoffs
- A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
- The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
Regulatory note: the FDA issued a warning letter to Ivim Services LLC dba Ivim in February 2026. We still list and link to Ivim Health; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.